Centre Amends Drugs Rules, 1945 to Ensure Uniform Regulation of Advanced Cell and Gene Therapies

Have sufficient facts (4+ from Tier 1 sources: PIB primary release, PIB related cough-syrup amendment release, CDSCO New Drugs and Clinical Trials Rules 2019). Writing the note.

Centre Amends Drugs Rules, 1945 for Uniform Regulation of Advanced Cell and Gene Therapies

1. At a Glance

• Central Government amended the Drugs Rules, 1945 to bring Cell/Stem Cell-derived products, Gene Therapeutic products, and Xenografts under the Centrally License Approving Authority (CLAA) framework, ensuring joint Centre-State regulatory oversight [S1].
• Significant for UPSC as it links health governance, federalism in drug regulation, and emerging biotech (CAR-T therapy, gene editing) — a recurring GS-II/GS-III theme [S1].
• Issued by the Ministry of Health and Family Welfare on 2 July 2026 [S1].
• Builds on India's existing biologics regulatory architecture under the New Drugs and Clinical Trials Rules, 2019 [S3].

2. Why in the News

• PIB press release dated 2 July 2026 announced the amendment expanding CLAA to cover advanced cell and gene therapy products and xenografts [S1].
• Comes amid rapid clinical adoption of technologies like CAR-T cell therapy for blood cancers and gene-editing therapeutics in India [S1].

3. Background & Evolution

• Drugs Rules, 1945 framed under the Drugs and Cosmetics Act govern manufacture, sale, and licensing of drugs in India; amended periodically (e.g., cough syrup sale exemption in small villages withdrawn via a separate 2026 amendment) [S2].
• Under the Act, certain critical drug/biological categories are placed under joint Central-State regulatory supervision via the CLAA route rather than State authorities alone [S1].
• Pre-amendment CLAA categories: vaccines, large volume parenterals (IV solutions >100 ml), and r-DNA based medicines [S1].
• New Drugs and Clinical Trials Rules, 2019 already classified vaccines, r-DNA derived products, Living Modified Organisms (LMOs), stem cell-derived products, and gene therapeutic products as "new drugs" requiring special scrutiny — the 2026 amendment extends this logic into the licensing (CLAA) framework specifically [S3].
• The 2026 amendment marks formal integration of stem cell/gene therapy/xenograft products into the licensing approval mechanism, not just the "new drug" classification [S1].

4. Core Static Facts

5. Multi-Dimensional Analysis

Scientific/Technological - Formal regulatory recognition of CAR-T cell therapy, gene editing/replacement therapeutics, and xenotransplantation products as India scales up domestic biotech capability [S1]. - Reflects convergence of biologics regulation with fast-evolving cell/gene therapy science globally [S1].

Legal/Administrative - Strengthens Centre-State joint regulatory supervision, shifting these high-risk product categories from sole state jurisdiction to the dual CLAA mechanism [S1]. - Part of a pattern of frequent rule-level amendments to the Drugs Rules, 1945 (e.g., a separate 2026 amendment withdrew cough syrup sale exemptions in small villages) [S2].

Governance/Public Health Safety - Aims for uniformity in regulatory standards across states, reducing regulatory arbitrage/inconsistency in high-risk biologic approvals [S1]. - Seeks alignment with global best practices in advanced therapy regulation [S1].

Economic - Balances patient safety with promoting innovation and faster technology adoption in India's healthcare/life sciences sector, relevant to biotech investment climate [S1].

Social - Directly affects patient access/safety for cancer, genetic disorder, and organ-replacement (xenograft) treatments [S1].

6. Recent Developments (last 12–18 months)

• 2 July 2026: MoHFW amends Drugs Rules, 1945 to bring cell/stem cell products, gene therapeutics, and xenografts under CLAA [S1].
• Separately, MoHFW amended Drugs Rules, 1945 to withdraw the exemption permitting sale of cough syrups in small villages without a licensed pharmacist, indicating continued regulatory tightening under the same Rules [S2].

7. Prelims Hooks

• The amendment in the news pertains to the Drugs Rules, 1945, not the Drugs and Cosmetics Act itself [S1].
• Nodal ministry: Ministry of Health and Family Welfare [S1].
• The regulatory mechanism expanded is the Centrally License Approving Authority (CLAA) [S1].
• Newly brought under CLAA: Cell/Stem Cell-derived products, Gene Therapeutic products, Xenografts [S1].
• Pre-existing CLAA categories included vaccines, large volume parenterals (IV >100 ml), and r-DNA based medicines [S1].
• "Large volume parenterals" specifically refers to IV solutions exceeding 100 ml [S1].
• CLAA represents joint Central-State regulatory supervision, not exclusive Central control [S1].
• Xenografts = animal-tissue-derived medical products (e.g., heart valves) [S1].
• CAR-T cell therapy is used to treat blood cancers (leukemias, lymphomas) [S1].
• The New Drugs and Clinical Trials Rules, 2019 already classify stem cell-derived and gene therapeutic products as "new drugs" [S3].
• CDSCO functions as India's National Regulatory Authority (NRA) for drugs [S3].
• CDSCO operates under the Directorate General of Health Services (DGHS), MoHFW [S3].
• A separate 2026 Drugs Rules amendment withdrew the cough syrup sale exemption for small villages [S2].

8. Mains Relevance

• GS-II: Government policies and interventions in the health sector; issues relating to development and management of Social Sector/Services (Health) [S1].
• GS-III: Science and Technology — developments in biotechnology; issues relating to intellectual property rights and their regulation [S1].
• Possible question stems: 1. "Discuss the significance of bringing advanced cell and gene therapies under the Centrally License Approving Authority (CLAA) framework. How does this strengthen India's drug regulatory architecture?" (GS-II/III) 2. "Examine the challenges in regulating emerging biomedical technologies such as gene therapy and xenotransplantation in India." (GS-III) 3. "Federal drug regulation in India involves both Central and State authorities. Critically analyse the rationale for joint oversight in the case of high-risk biologics." (GS-II)

9. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 — parent statute enabling the Drugs Rules, 1945 [S1].
• New Drugs and Clinical Trials Rules, 2019 — classifies gene/stem cell products as "new drugs," directly linked framework [S3].
• CDSCO structure and functions — India's national drug regulator [S3].
• CAR-T cell therapy in India — indigenous approvals and cost/access debates.
• National Biopharma Mission / BIRAC — biotech innovation funding ecosystem relevant to cell/gene therapy R&D.
• Xenotransplantation ethics and regulation — global comparative angle (WHO guidance).
• Ayushman Bharat and access to high-cost advanced therapies — health equity angle.
• Essential Commodities Act/pricing of biologics — access and affordability dimension.

10. Common Errors / Trap Areas

• Confusing CLAA (licensing authority) with CDSCO (the regulatory organisation) — CLAA operates under CDSCO's oversight framework, not a separate body [S1][S3].
• Assuming the amendment is under the Drugs and Cosmetics Act directly — it is specifically an amendment to the subordinate Drugs Rules, 1945 [S1].
• Mixing up this amendment with the New Drugs and Clinical Trials Rules, 2019, which already classified these products as "new drugs" but did not itself establish the CLAA licensing inclusion announced in 2026 [S1][S3].
• Misremembering "large volume parenterals" threshold — it is IV solutions exceeding 100 ml, not any arbitrary volume [S1].
• Conflating this cell/gene therapy amendment with the unrelated 2026 cough syrup sale exemption withdrawal — both amend the same Drugs Rules, 1945 but address different issues [S1][S2].

11. Sources

• [S1] Centre Amends Drugs Rules, 1945 to Ensure Uniform Regulation of Advanced Cell and Gene Therapies — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2280408 — (tier: 1)
• [S2] Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945; Exemption for Sale of Cough Syrups in Small Villages Withdrawn — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2273373&reg=3&lang=1 — (tier: 1)
• [S3] New Drugs and Clinical Trials Rules, 2019 — CDSCO — https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/New-Drugs/ — (tier: 1)